PCK2 Inhibition Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Triggering Ferroptosis
The FASEB Journal · 2026
DOI: 10.1096/fj.202602464r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Jing Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, Clinical diagnosis and Treatment Technology Innovation Project, Jiangsu Provincial Medical Key Discipline.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) accounts for ~85% of lung cancers, with platinum‐based chemotherapy as the main treatment. Ferroptosis has been implicated in cancer chemoresistance, yet the molecular mechanisms linking metabolic reprogramming to ferroptosis‐mediated cisplatin resistance in NSCLC remain elusive. In this study, we found that phosphoenolpyruvate carboxykinase 2 (PCK2), a metabolic reprogramming enzyme, was significantly upregulated, and its overexpression enhanced ferroptosis resistance, thereby promoting cisplatin chemoresistance. Mechanistically, RGB‐286638 free base (RGB) inhibits PCK2 expression by directly binding to its R454 site to activate ferroptosis in cisplatin‐resistant cells and restores cisplatin sensitivity both in vitro and in vivo. Targeting PCK2 with RGB provides a promising strategy to overcome chemoresistance, facilitating improved clinical interventions for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Respiratory Medicine, Taixing Second People's Hospital, Taixing, China.
- Institute of Respiratory Diseases, Soochow University, Suzhou, China.
- Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Yuanyuan Zeng
Förderung
- National Nature Science Foundation of China
- Clinical diagnosis and Treatment Technology Innovation Project
- Jiangsu Provincial Medical Key Discipline
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Wang, Z., Gu, C., Chen, Y., Yang, Y., Zhu, J., Zhang, Y., Shao, Y., Pang, X., Ge, Y., Qian, H., Huang, J. A., Liu, Z., Zeng, Y., & Ji, C. (2026). PCK2 Inhibition Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Triggering Ferroptosis. The FASEB Journal. https://doi.org/10.1096/fj.202602464r
Vancouver
Liu J, Wang Z, Gu C, Chen Y, Yang Y, Zhu J, et al. PCK2 Inhibition Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Triggering Ferroptosis. The FASEB Journal. 2026. doi:10.1096/fj.202602464r
BibTeX
@article{Liu2026,
author = {Liu, Jing and Wang, Ziyan and Gu, Chen and Chen, Yili and Yang, Yang and Zhu, Jianjie and Zhang, Yihua and Shao, Yuna and Pang, Xiaodong and Ge, Yujie and Qian, Huiwen and Huang, Jian-An and Liu, Zeyi and Zeng, Yuanyuan and Ji, Cheng},
title = {PCK2 Inhibition Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Triggering Ferroptosis},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202602464r}
}
EUVIMED